Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Date
2020
Author
Gleixner, Karoline
Nekvindova, Lucie
Elberink, Hanneke O.
Gorska, Aleksandra
Lange, Magdalena
Hartmann, Karin
Illerhaus, Anja
Bonifacio, Massimiliano
Perkins, Cecelia
Elena, Chiara
Niedoszytko, Marek
van Anrooij, Bjorn
Reiter, Andreas
Gotlib, Jason
Kluin-Nelemans, Hanneke C.
Mayer, Jiri
Doubek, Michael
Valent, Peter
Malcovati, Luca
Fortina, Anna B.
Yavuz, Akif
Hagglund, Hans
Mattsson, Mattias
Panse, Jens
Jaekel, Nadja
Kilbertus, Alex
Hermine, Olivier
Arock, Michel
Fuchs, David
Sabato, Vito
Brockow, Knut
Bretterklieber, Agnes
Shoumariyeh, Khalid
Jawhar, Mohamad
Zanotti, Roberta
Bonadonna, Patrizia
Caroppo, Francesca
Zink, Alexander
Triggiani, Massimo
Parente, Roberta
von Bubnoff, Nikolas
Trizuljak, Jakub
Sperr, Wolfgang R.
Metadata
Show full item record
Abstract
Background: In indolent systemic mastocytosis (ISM), several risk factors of disease progression have been identified. Previous studies, performed with limited patient numbers, have also shown that the clinical course in ISM is stable and comparable to that of cutaneous mastocytosis (CM). The aim of this project was to compare the prognosis of patients with ISM with that of patients with CM.
URI
http://hdl.handle.net/20.500.12627/3808
https://doi.org/10.1111/all.14248
Collections